

## LIDDS has decided to write-down intangible assets

**GOTHENBURG, SWEDEN – The board of directors of LIDDS AB (publ) has, taking into account the principle of prudence, decided to write down the book values of all intangible assets in LIDDS AB and Noviga Research AB as of 2024-12-31.**

Following the board's decision on April 2, to terminate further development of the project areas Nanodotax, Nanoimod and NOV 202, the board has decided to write down the book values of intangible assets regarding development work and patents. Even though there may be significant values for these assets in the context of sales, the board has decided to take the principle of prudence into account. The write-downs will take place as of year-end 2024/2025, which will result in a deviation for the annual report compared to the published year-end report 2024.

For LIDDS AB, the impairment will amount to SEK 1.4 MSEK and for Noviga Research AB to SEK 1.2 MSEK. After the impairments, the carrying amount of intangible assets amounts to 0 SEK in both companies.

**For additional information, please contact**

---

Mats Wiking, CEO and CFO  
Phone: +46 (0)70 620 04 00  
E-mail: [mats.wiking@liddspharma.com](mailto:mats.wiking@liddspharma.com)

Daniel Lifveredson, Chairman of the Board  
Telefon: +46 (0) 70-916 21 01  
Email: [d.li@excore.com](mailto:d.li@excore.com)

LIDDS' Certified Adviser is Redeye AB

### **LIDDS in brief:**

---

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

*This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-10 13:30 CEST.*

## Attachments

---

**LIDDS has decided to write-down intangible assets**